$53.07
0.12% today
Nasdaq, Feb 28, 04:47 pm CET
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Rhythm Pharmaceuticals, Inc. Stock price

$53.00
-3.52 6.23% 1M
+5.57 11.74% 6M
-2.98 5.32% YTD
+6.97 15.14% 1Y
+45.38 595.54% 3Y
+34.85 191.93% 5Y
+23.00 76.67% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.32 0.60%
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Key metrics

Market capitalization $3.26b
Enterprise Value $3.08b
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 23.69
P/S ratio (TTM) P/S ratio 25.03
P/B ratio (TTM) P/B ratio 152.18
Revenue growth (TTM) Revenue growth 68.06%
Revenue (TTM) Revenue $130.13m
EBIT (operating result TTM) EBIT $-265.51m
Cash position $320.57m
EPS (TTM) EPS $-4.36
P/E forward negative
P/S forward 17.47
EV/Sales forward 16.54
Short interest 12.61%
Show more

Is Rhythm Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Rhythm Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Rhythm Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
130 130
68% 68%
100%
- Direct Costs 14 14
36% 36%
11%
117 117
75% 75%
90%
- Selling and Administrative Expenses 144 144
25% 25%
111%
- Research and Development Expense 237 237
77% 77%
182%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -266 -266
44% 44%
-204%
Net Profit -261 -261
41% 41%
-200%

In millions USD.

Don't miss a Thing! We will send you all news about Rhythm Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rhythm Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
2 days ago
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants David Connolly – Investor Relations and Corporate Communications David Meeker – Chairman, Chief Executive Officer and President Jennifer Lee – Executive Vice President, Head-North America Hunter Smith – Chief Financial Officer Yann Mazabraud – Executive Vice President, ...
Neutral
GlobeNewsWire
2 days ago
-- Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 --  -- Completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity -- -- FDA approved expanded lab...
Positive
Seeking Alpha
3 days ago
Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on Rhythm's robust clinical progress and strategic positioning in the rare genetic obesity market. Rating justification is based on solid revenues, innovative product pipeline, and potential market expan...
More Rhythm Pharmaceuticals, Inc. News

Company Profile

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Head office United States
CEO David Meeker
Founded 2008
Website www.rhythmtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today